Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:food:aim_health:aging [01.11.2019]
sallieq [General research on aging]
home:food:aim_health:aging [03.13.2019] (current)
sallieq [with additional studies]
Line 1: Line 1:
  
  
-====== ​Aging and Olmesartan ======+====== ​Health Maintenance ​and Olmesartan ======
  
 Summary of research on aging and Olmesartan Summary of research on aging and Olmesartan
Line 8: Line 8:
 ===== with additional studies ===== ===== with additional studies =====
  
- ​Benefits ​of RAS blockade with olmesartan treatment are sustained after study discontinuation.  (({{pubmed>​long:​24772521}}))+Clinical studies have demonstrated that some antihypertensive agents provide renoprotection independent ​of BP lowering.  (({{pubmed>​long:​16236804}})) 
  
- In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>​long:​24535009}})) ​  + ​Although uncontrolled confounding might still exist, ​(//this was a short term study//​) ​olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>​long:​24516110}})) ​
- +
- Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>​long:​24516110}})) ​+
  
  The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>​long:​16508590}})) ​  The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>​long:​16508590}})) ​
  
-The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>​long:​27082551}})) ​+ ​Benefits of RAS blockade with olmesartan treatment are sustained after study discontinued. ​ (({{pubmed>​long:​24772521}})) 
 + 
 +Olmesartan and Bay11-7082 inhibit the MCF-7 cells growth indicating RAS and NF-kappaB pathway blockade lead to cytotoxicity and apoptosis induction against tumour cells. ​  (in breast cancer)(({{pubmed>​long: ​   26138656}})) 
 + 
 +Data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>​long:​27082551}})) ​ 
 + 
 +Administration of olmesartan suppressed the accumulation of macrophages in  brachiocephalic atherosclerotic plaque. (in mice) (({{pubmed>​long: ​   20079903}}))  
 + 
 +Olmesartan significantly reduced myocardial infarct size and improved LV contractility at a dose (**3 mg/kg**) with systemic vasodilating effects but not at a lower dose (0.3 mg/kg) without hemodynamic effects.(in rat)  
 + 
 +Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.  (({{pubmed>​long:​24379062}}))  
 + 
 +Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pubmed>​long: ​   19927151}}))  
 + 
 +Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. (({{pubmed>​long:​19304450}}))  
 + 
 +Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>​long:​26239632}}))  
 + 
 + In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>​long:​24535009}}))  ​
  
-Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>​long:​26239632}})) ​ 
  
 ==== General research on aging ==== ==== General research on aging ====
  
-Falls studies have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, ​recurrent fallsand injurious falls. (({{pubmed>​long:​25539567}})) +Holistic vitamin D supplementation with or without calcium ​is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin Ddaily or as a bolusdoes not reduce the risk of cardiovascular events. (({{pubmed>​long:​30601231}})) 
  
- These articles ​have identified holistic vitamin D supplementation with or without calcium ​is unlikely to be an effective primary prevention strategy for falls or fracture. There has also been high-quality evidence that vitamin Ddaily or as a bolusdoes not reduce the risk of cardiovascular events. (({{pubmed>​long:​30601231}})) +When using off-label Olmesartan, patients are observed to need fewer other pharmaceutical preparations to maintain and improve health status. ​ Falls studies ​have determined that taking ≥ 4 drugs is associated with an increased incidence of falls, ​recurrent fallsand injurious falls. (({{pubmed>​long:​25539567}})) 
 ==== Some of the documented protective effects of ARBs ==== ==== Some of the documented protective effects of ARBs ====
  ​include the ability to:   ​include the ability to: 
Line 32: Line 47:
   * inhibit liver fibrosis and aid liver healing(({{pubmed>​long:​12871826}}))   * inhibit liver fibrosis and aid liver healing(({{pubmed>​long:​12871826}}))
   * reduce insulin resistance in rats(({{pubmed>​long:​15127887}}))   * reduce insulin resistance in rats(({{pubmed>​long:​15127887}}))
-  * 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed>​long:​23775504}}))+  ​* **6 mg/kg** olmesartan reduces the inflammatory process and bone loss in rats(({{pubmed>​long:​23775504}}))
   * protect the mitochondria from age-associated damage from oxidation(({{pubmed>​long:​12709417}}))   * protect the mitochondria from age-associated damage from oxidation(({{pubmed>​long:​12709417}}))
   * play a protective role against proliferative diabetic retinopathy (({{pubmed>​long:​17560613}}))   * play a protective role against proliferative diabetic retinopathy (({{pubmed>​long:​17560613}}))
Line 83: Line 98:
 === A number of studies have found === === A number of studies have found ===
  
-that olmesartan ​and other ARBs possess ​various ways of protecting the kidneys from the effects of inflammation and cytokine damage: ​+that olmesartan ​possesses ​various ways of protecting the kidneys from the effects of inflammation and cytokine damage: ​
  
   * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated,​ and Olmesartan partly restored the synchronization (({{pubmed>​long:​23511341}})) ​   * in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated,​ and Olmesartan partly restored the synchronization (({{pubmed>​long:​23511341}})) ​
   * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>​long:​23154587}})) ​   * in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition (({{pubmed>​long:​23154587}})) ​
-  * results suggest olmesartan can help decrease plasma AGE levels in patients on HD (({{pubmed>​long:​22149003}}))  +  * results suggest olmesartan can help decrease plasma AGE levels in patients on Hemodialysis ​(({{pubmed>​long:​22149003}}))  
-  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>​long:​3862195}})) +  * renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>​long:​24384547}}))     ​
   * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects ​ (({{pubmed>​long:​24842388}})) ​   * olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects ​ (({{pubmed>​long:​24842388}})) ​
  
  
  
-=== Recent studies ​showed ===+=== Studies also showed ===
  
  
Line 110: Line 125:
 === Long term treatment === === Long term treatment ===
  
-Data suggest 40 80 mg olmesartan ​are able to significantly remodel ​destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. + ​Patients receiving the highest dose of olmesartan (40 and 80 mg) had an inward carotid remodeling and were shifted toward a lower elastic modulus at a given circumferential wall stress, indicating an improvement in the intrinsic elastic properties of the carotid artery wall material. These data suggest ​that 40 and 80 mg olmesartan ​were able to significantly remodel ​and destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. 
 //​hyper.ahajournals.org/​content/​early/​2014/​07/​07/​HYPERTENSIONAHA.114.03282.reprint ​ (({{pubmed>​long:​25001274}})) //​hyper.ahajournals.org/​content/​early/​2014/​07/​07/​HYPERTENSIONAHA.114.03282.reprint ​ (({{pubmed>​long:​25001274}}))
  
 {{tag>​olmesartan Food_and_drink summary}} {{tag>​olmesartan Food_and_drink summary}}
  
home/food/aim_health/aging.1547173029.txt.gz · Last modified: 01.11.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.